Pioneering a New Path for Rare CNS Disorders
Zy Therapeutics is developing ZY-001, the first potential disease-modifying therapy to directly target brain calcifications — an overlooked driver of seizures and cognitive decline.
Our Focus
Targeting the Root Cause, Not Just the Symptoms
At Zy Therapeutics, we are a rare disease biotech company focused on a critical unmet need: intracranial calcifications. These “brain stones” are calcium-phosphate deposits that disrupt normal neuronal signaling, leading to seizures, developmental challenges, and cognitive decline in devastating rare CNS disorders.
Our mission is to transform brain calcification from an untreatable symptom into a treatable target.
Our Solution
Introducing ZY-001: A First-in-Class Approach
We are advancing ZY-001 (disodium etidronate), a novel, CNS-targeted formulation of a proven molecule. By re-engineering this compound for enhanced absorption and brain delivery, ZY-001 is designed to directly chelate excess calcium and normalize tissue mineral balance, offering the first potential disease-modifying treatment for conditions driven by pathological calcium buildup.
Who We Serve
Addressing Devastating Rare Diseases
Our initial focus is on rare neurological disorders where brain calcification is a primary driver of disease burden.
Sturge-Weber Syndrome (SWS)
Targeting calcifications linked to seizures and cognitive decline.
Tuberous Sclerosis Complex (TSC)
Addressing calcified tubers that contribute to drug-resistant epilepsy.
Neurocysticercosis
Neutralizing calcified lesions that remain a source of seizures.
Fahr’s Disease (PFBC)
Aiming to slow or reverse progressive movement and cognitive symptoms.
Our Commitment
Science with Purpose, Medicine with Meaning
Our team brings over 100 years of combined expertise in rare CNS disorders, clinical epilepsy research, and translational neuroscience. As scientists and clinicians, we are driven by a single goal: to turn scientific insight into life-changing therapies for those who currently have none.
News & Events
Advancing Our Science and Engaging Our Community
News
Building Strategic Partnerships at AES 2025
As Zy Therapeutics prepares for the 2025 American Epilepsy Society (AES) Annual Meeting, the company is placing a strong emphasis on building the strategic relationships needed to advance…
Read MoreEvents
Zy Therapeutics at AES 2025: Advancing Treatments for Rare Epilepsies
- December 5-9, 2025 | Atlanta - Zy Therapeutics will be attending AES 2025 in Atlanta, Georgia, where the team will highlight ongoing work toward developing a disease-modifying…
More InfoZy Therapeutics at the SWFIRN & CCN Conference: Advancing Collaboration in Sturge-Weber Research
- September 18–20, 2025 | Madison, WI - Zy Therapeutics is pleased to announce that our Chief Medical & Scientific Officer, Dr. Jeffrey Loeb, will be attending the…
More InfoZy Therapeutics at WONOEP 2025: Showcasing Innovation in Epilepsy Research
- August 30 - September 3, 2025 | Lisbon, Potrugal - Zy Therapeutics is excited to announce that our CMO, Dr. Jeffrey Loeb, will be speaking at the…
More Info